Immunohistochemical Expression of HER2/neu in Invasive Ductal Carcinoma of Breast


PDF PDF

Keywords

Invasive ductal carcinoma
HER2/neu
Immunohistochemistry
Breast cancer
and Histopathological grade

How to Cite

1.
Immunohistochemical Expression of HER2/neu in Invasive Ductal Carcinoma of Breast. The Insight [Internet]. 2026 Nov. 15 [cited 2026 Nov. 17];9(03):978-82. Available from: https://bdjournals.org/insight/article/view/1669

Abstract

Background: Globally, breast cancer remains a leading malignancy among women, while in Bangladesh, delayed diagnosis and limited access to specialized biomarker testing continue to challenge optimal management. Among invasive breast cancers, HER2/neu expression is clinically important because it reflects tumor biology and guides HER2-targeted therapy. Aim of the study: This study aimed to determine HER2/neu immunohistochemical expression in invasive ductal carcinoma of the breast and assess its relationship with selected clinicopathological characteristics. Methods & Materials: This cross-sectional observational study included 52 histologically confirmed cases of invasive ductal carcinoma of the breast diagnosed at the Department of Pathology, Chittagong Medical College, and CARE Investigation, Chattogram, using consecutive sampling from March 2018 to February 2020. Formalin-fixed, paraffin-embedded tissue sections were examined histologically and graded, while HER2/neu expression was assessed by immunohistochemistry using a rabbit polyclonal antibody. HER2/neu staining was categorized as negative, weakly positive, or strongly positive. Data were analyzed using SPSS version 26.0, and associations with selected clinicopathological variables were assessed, with p<0.05 considered statistically significant. Results: The mean patient age was 48.33 ± 10.81 years (range: 21-73 years), and 98.1% were female. Grade II invasive ductal carcinoma was predominant, accounting for 75.0% of cases, followed by Grade III, 21.2%, and Grade I, 3.8%. Strong HER2/neu expression was observed in 48.1%, weak positivity in 30.8%, and negative expression in 21.2%. No significant association was found between HER2/neu expression and age (p=0.843), estrogen exposure (p=0.116), or tumor grade (p=0.161). Among strongly positive tumors, 80.0% were Grade II. Conclusion: HER2/neu overexpression was common in invasive ductal carcinoma, particularly among Grade II tumors, but showed no significant association with age, estrogen exposure, or tumor grade. Accurate HER2 assessment is therefore important for prognostic evaluation and selecting appropriate targeted therapy.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2026 The Insight